Writer, speaker, science geek, cancer research advocate and activist. Living with ROS1 lung cancer since 2011. Cofounder @ros1cancer, @IASLC STARS. #LCSM
Hm. X says my account is based in Malaysia. I was recently on a cruise from Tokyo to Bangkok with shipboard wifi provided by Starlink. I logged into X ONCE (on the South China Sea between Hong Kong and Taiwan), 100s of miles from Malaysia. Methinks the algorithm needs more work.
If anyone knows @DRCamidge, they know how patient-focused he's been in his 20 years of leading lung cancer research. (And funny - just ask @JFreemanDaily 😉 .)
But he hasn't been doctor only - he's been a stage 4 lung cancer patient, himself. Recently, he decided to open up about his experience after learning of his diagnosis 3 years ago.
I had the privilege of hearing more about his experience firsthand and am grateful to him for continuing to help people, in spite of his incredibly busy schedule (BTW this was the 2nd time in 1 month he gave us @Patient_Story his time. The 1st was for our partnership with @ros1cancer on an educational series).
Want inspiration on how to approach life? Take a look & listen 👇
thepatientstory.com/patient-…#lungcancer#cancerawareness#stage4#patientcare
@ComcastCares I use @SaneBox to keep my Inbox under control but you keep blocking their access to my @comcast email account! What gives? Please stop blocking their access to my account! bit.ly/3w1Eazs
FDA approves taletrectinib for #ROS1 NSCLC based on TRUST I and TRUST II trials showing 1L RR 85-90% with 63-72% of responses lasting ≥12 months and post TKI, RR 52-62%. Taletrectinib has selectivity over TrkB so should have less neurotoxicity.
fda.gov/drugs/resources-info…
The entire STAT staff is updating this story about layoffs at HHS. There will be a lot of info.
But the short version is this: a lot of the people who would keep drugs safe and effective, to protect patients in trials, and to fight bird flu and future pandemics are gone -- even though it seems the scientists in charge of directly reviewing new medicines are mostly protected at FDA.
Per Robert Califf: "[The FDA] as we’ve known it is finished, with most of the leaders with institutional knowledge and a deep understanding of product development and safety no longer employed.”
statnews.com/2025/04/01/hhs-…
My approach to treatment is: I’m not looking to throw a Hail Mary touchdown — the odds aren’t in my favor. I need to keep getting first downs. First downs keep me in the game, and the longer I'm in the game, the more time research has to catch up!
22 first downs - think about all the moments and milestones this patient was able to experience with family & friends thanks to SBRT. That is HOPE!
A thoughtful perspective on importance of government-supported research infrastructure. It's not perfect, and could use reform. But you can't reform something that disappeared due to lack of funding for labs, support staff, equipment and office space.
nytimes.com/2025/02/14/opini…
On this #WorldCancerDay, take steps to amp up your lung cancer patient advocacy! Applications are now open for the 2025 IASLC STARS PRA & Scholar Programs. STARS can help you develop and enhance research advocacy skills. iaslc-stars.org
DEI is not the same as diversity in clinical trials.
Diversity in clinical trials aims to test new drugs in a wide variety of people, because response to some medicines can vary by gender, age, ethnicity, and genetics.
statnews.com/2025/01/23/fda-…
As we embark on Thanksgiving week I want to take a moment to reflect on this year and my family. Unfortunately I lost my sister to lung cancer in August. It was devastating news when she was diagnosed in 2022 and it's still a shock to believe my vibrant, passionate, loving sister is gone. November is Lung Cancer Awareness Month. When Susan was diagnosed we had no idea that lung cancer was the number one cancer killer - killing more people than breast, prostate and colon cancer combined. There is also no universal screen the way there is for breast, prostate and colon. There is an urgent need for research to develop better screening methods for this deadly disease. Lung cancer can impact people who smoked and people who never smoked. Our family is committed to bringing awareness to lung cancer and working to develop earlier screening methods.
As we sit down for Thanksgiving this year with friends and family I want to share this quote from Susan's blog that she wrote a before she died.
"As a person I have changed a lot, and probably the most important lesson I have learned is just to focus and enjoy the present! Life is unpredictable for everyone, with many unknowns, but there is a lot of beauty in everyday life. My goals going forward are to enjoy the present as much as possible and fight for better understanding and cures for this disease."
May you all enjoy the moment, enjoy your friends and family and appreciate the beauty in everyday life.
blog.youtube/inside-youtube/…
When Susan was diagnosed with lung cancer we quickly learned we had many unanswered questions. We launched the @23andme Lung Cancer Community with the intention of getting answers. We brought together over 20 lung cancer advocacy organizations to collectively make a difference. Our goal for this study is to understand more about how our genetics influence lung cancer so we can improve detection, reduce risk, and have better treatment options. If you have lung cancer or know someone who has lung cancer, please encourage them to sign up.
23andme.com/lung-cancer/@LUNGevity@Exon20Group@ALKPositiveinc@ICANdecide@TheALCF@lcfamerica@metcrusaders@NTRKers@KRASKickers@ros1cancer@LCRFawareness
The physician’s duty is not to stave off death or return patients to their old lives, but to take into our arms a patient and family whose lives have disintegrated and work until they can stand back up and face—and make sense of—their own existence. @rocketgirlmd
Trying to surf the wave a little: For those up for a redux on all past @OncLive How This is Building Me podcasts on the people behind cancer, cancer medicine and cancer science - they will be slowly recommented on with links on @drcamidge.bluesky.social
A treat to hear about novel therapeutic frontiers in fusion positive NSCLC from Dr. Alice Shaw at #CFS24. Profound efficacy with targeted agents for #ALK#ROS1#RET fusion positive NSCLC - critical to identify these fusions when present. Exciting new drugs coming!